Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation
- 13 May 2021
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (04) , 480-491
Abstract
Patients supported with extracorporeal membrane oxygenation (ECMO) experience a very high frequency of bleeding and ischaemic complications, including stroke and systemic embolism. These patients require systemic anticoagulation, mainly with unfractionated heparin (UFH) to prevent clotting of the circuit and reduce the risk of arterial or venous thrombosis. Monitoring of UFH can be very challenging. While most centres routinely monitor the activated clotting time and activated partial thromboplastin time (aPTT) to assess UFH, measurement of anti-factor Xa (anti-Xa) level best correlates with heparin dose, and appears to be predictive of circuit thrombosis, although aPTT may be a better predictor of bleeding. Although monitoring of prothrombin time, platelet count and fibrinogen is routinely undertaken to assess haemostasis, there is no clear guidance available regarding the optimal test.Additional tests, including antithrombin level and thromboelastography, can be used for risk stratification of patients to try and predict the risks of thrombosis and bleeding. Each has their specific role, strengths and limitations. Increased thrombin generation may have a role in predicting thrombosis. Acquired von Willebrand syndrome is frequent with ECMO, contributing to bleeding risk and can be detected by assessing the von Willebrand factor activity-to-antigen ratio, while the platelet function analyser can be used in urgent situations to detect this, with a high negative predictive value. Tests of platelet aggregation can aid in the prediction of bleeding.To personalise management, a selection of complementary tests to collectively assess heparin-effect, coagulation, platelet function and platelet aggregation is proposed, to optimise clinical outcomes in these high-risk patients.Keywords
This publication has 80 references indexed in Scilit:
- Evaluation of a modified thromboelastography assay for the screening of von Willebrand diseaseThrombosis and Haemostasis, 2011
- Acquired von Willebrand Syndrome After Continuous-Flow Mechanical Device Support Contributes to a High Prevalence of Bleeding During Long-Term Support and at the Time of TransplantationJACC, 2010
- Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life supportThrombosis Research, 2010
- High rate of unprovoked recurrent venous thrombosis is associated with high thrombin‐generating potential in a prospective cohort studyJournal of Thrombosis and Haemostasis, 2008
- Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrenceBritish Journal of Haematology, 2007
- Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on SurvivalThe Annals of Thoracic Surgery, 2007
- Assessing Heparin Dosing in Neonates on Venoarterial Extracorporeal Membrane OxygenationASAIO Journal, 2007
- Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?Thrombosis Research, 2007
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Heparin resistance after preoperative heparin therapy or intraaortic balloon pumpingThe Annals of Thoracic Surgery, 1994